A049960 Stock Overview
Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Cell Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,150.00 |
| 52 Week High | ₩14,590.00 |
| 52 Week Low | ₩10,500.00 |
| Beta | 0.85 |
| 1 Month Change | -1.22% |
| 3 Month Change | 1.84% |
| 1 Year Change | -11.05% |
| 3 Year Change | -35.88% |
| 5 Year Change | -59.97% |
| Change since IPO | 305.00% |
Recent News & Updates
Recent updates
Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their Portfolio
May 05
Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?
Mar 18A Look At Cell Biotech's (KOSDAQ:049960) Share Price Returns
Feb 25Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% Dividend
Feb 04
Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?
Jan 14Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-Dividend
Dec 24Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Dec 13Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five Years
Nov 18Shareholder Returns
| A049960 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.9% | 5.4% | 3.4% |
| 1Y | -11.1% | 6.7% | 7.1% |
Price Volatility
| A049960 volatility | |
|---|---|
| A049960 Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 122 | Myung-Jun Jung | www.cellbiotech.com |
Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally. It engages in the probiotics, microbiome, and anticancer new drug businesses. The company sells its products through partnerships with multinational companies and local retailers under the DUOLAC, DUOLAB, LACTOClear, and LAB2PRO brand names.
Cell Biotech Co., Ltd. Fundamentals Summary
| A049960 fundamental statistics | |
|---|---|
| Market cap | ₩83.15b |
| Earnings (TTM) | ₩6.30b |
| Revenue (TTM) | ₩53.79b |
13.2x
P/E Ratio1.5x
P/S RatioIs A049960 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A049960 income statement (TTM) | |
|---|---|
| Revenue | ₩53.79b |
| Cost of Revenue | ₩15.14b |
| Gross Profit | ₩38.65b |
| Other Expenses | ₩32.34b |
| Earnings | ₩6.30b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 921.07 |
| Gross Margin | 71.85% |
| Net Profit Margin | 11.72% |
| Debt/Equity Ratio | 0% |
How did A049960 perform over the long term?
See historical performance and comparison